Exhibit 13(a) - Methodology for Librela FDA CVM Adverse Event Analysis Through Q4 2025
NonrulemakingSupporting & Related MaterialFDA-2026-P-6249-0021
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- Jun 3, 2026
- Agency
- Food and Drug Administration (FDA)